FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
HEMATOLOGY
PAPER-III
HEMAT/J/20/48/III
Max. Marks:100
Important Instructions:
Attempt al questions in order.
Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Pre-operative bleeding assessment:
3+3+4
b) Limitations of screening coagulation tests.
c) Describe the tool most used for bleeding assessment.
2. Polycythemia vera (PV):
4+3+3
haemoglobin of 17g/dl?
b) What is the utility of al ele burden?
c) What is the treatment recommendations for PV?
3. Ruxolinitib:
a) What study led to its approval in primary myelofibrosis (PMF)?
b) Discuss the dose modifications in patients being treated for PMF.
c) When is it indicated in polycythemia vera?
4. COVID-19:
a) What coagulation abnormalities do we see with COVID-19?
b) How do these differ from Disseminated intravascular coagulation
(DIC)?
c) What prognostic tests/values have been found to be useful in prediction
5. Anti-coagulation in COVID-19:
3+3+4
a) What are the current guidelines for thrombo-prophylaxis in moderate
and severe COVID-19 patients?
c) Discuss evidence for or against extended prophylaxis very
therapeutic anticoagulation.
P.T.O
-1-
EXAMINATION HALL.
FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
PAPER-III
6. In acute myeloid leukemia discuss-
5+5
a) Molecular risk stratification and methods for assessment of measurable
b) Which molecular targets cannot be used for measurable residual disease
assessment (MRD). Explain why?
7. a) How do patients with primary hemostatic defects present?
4+3+3
thrombasthenia? How wil you confirm the diagnosis?
c) How should such patients be managed? What complications are
anticipated?
8. A 14-year-old boy receives induction therapy for B cell acute lymphoblastic 4+4+2
positive.
a) Discuss what therapy options are now indicated for him?
b) If he becomes MRD negative, what is the prognosis? On what factors
does ALL prognosis depend?
9. a) What novel non-factor haemophilia agent is approved for Hemophilia A?
3+3+4
b) What is the recommended dose and mode of administration?
c) How does this product work? How can it be monitored?
4+3+3
b) How do molecular mutations affect therapy choices?
c) In a patient with low risk myelodysplastic syndrome, what options are
there for treating anemia?
-2-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
HEMATOLOGY
PAPER-III
--- Content provided by FirstRanker.com ---
Time: 3 hoursHEMAT/J/20/48/III
Max. Marks:100
Important Instructions:
Attempt al questions in order.
--- Content provided by FirstRanker.com ---
Each question carries 10 marks.Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
--- Content provided by FirstRanker.com ---
Start the answer to a question on a fresh page or leave adequate space between two answers.Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Pre-operative bleeding assessment:
3+3+4
--- Content provided by FirstRanker.com ---
a) How is a pre-operative patient to be evaluated for risk of bleeding?b) Limitations of screening coagulation tests.
c) Describe the tool most used for bleeding assessment.
2. Polycythemia vera (PV):
4+3+3
--- Content provided by FirstRanker.com ---
a) How wil you work up a woman of 50 years of age, JAK2 negative withhaemoglobin of 17g/dl?
b) What is the utility of al ele burden?
c) What is the treatment recommendations for PV?
3. Ruxolinitib:
--- Content provided by FirstRanker.com ---
4+4+2a) What study led to its approval in primary myelofibrosis (PMF)?
b) Discuss the dose modifications in patients being treated for PMF.
c) When is it indicated in polycythemia vera?
4. COVID-19:
--- Content provided by FirstRanker.com ---
4+4+2a) What coagulation abnormalities do we see with COVID-19?
b) How do these differ from Disseminated intravascular coagulation
(DIC)?
c) What prognostic tests/values have been found to be useful in prediction
--- Content provided by FirstRanker.com ---
of hypercoagulable state?5. Anti-coagulation in COVID-19:
3+3+4
a) What are the current guidelines for thrombo-prophylaxis in moderate
and severe COVID-19 patients?
--- Content provided by FirstRanker.com ---
b) What recommendations are there for patients on ventilator in the ICU?c) Discuss evidence for or against extended prophylaxis very
therapeutic anticoagulation.
P.T.O
-1-
--- Content provided by FirstRanker.com ---
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THEEXAMINATION HALL.
FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
--- Content provided by FirstRanker.com ---
HEMATOLOGYPAPER-III
6. In acute myeloid leukemia discuss-
5+5
a) Molecular risk stratification and methods for assessment of measurable
--- Content provided by FirstRanker.com ---
minimal residual disease (MRD) assessments.b) Which molecular targets cannot be used for measurable residual disease
assessment (MRD). Explain why?
7. a) How do patients with primary hemostatic defects present?
4+3+3
--- Content provided by FirstRanker.com ---
b) Describe the platelet function reports in a patient of Glanzmannthrombasthenia? How wil you confirm the diagnosis?
c) How should such patients be managed? What complications are
anticipated?
8. A 14-year-old boy receives induction therapy for B cell acute lymphoblastic 4+4+2
--- Content provided by FirstRanker.com ---
leukemia. After induction, he has measurable residual disease(MRD)positive.
a) Discuss what therapy options are now indicated for him?
b) If he becomes MRD negative, what is the prognosis? On what factors
does ALL prognosis depend?
--- Content provided by FirstRanker.com ---
c) What should be the best therapy option now?9. a) What novel non-factor haemophilia agent is approved for Hemophilia A?
3+3+4
b) What is the recommended dose and mode of administration?
c) How does this product work? How can it be monitored?
--- Content provided by FirstRanker.com ---
10. a) How do you risk stratify myelodysplastic syndrome?4+3+3
b) How do molecular mutations affect therapy choices?
c) In a patient with low risk myelodysplastic syndrome, what options are
there for treating anemia?
--- Content provided by FirstRanker.com ---
************-2-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
--- Content provided by FirstRanker.com ---